Indian pharmaceutical sector anticipates 8-10% growth driven by domestic expansion and regulated market exports

  • CRISIL analysis expects sales to increase 8-10% in 2023-24 fiscal year, fueled by domestic growth and increased exports.
  • The sector could also experience a 50-100 basis point improvement in operating profitability in this fiscal year, reaching approximately 21%.
  • The enforced claw-back taxes in specific European markets may impact growth of exports to Europe, while Asian markets are set to see improved growth.
Join 2 million subscribers

A curated newsletter that summarizes the important news at the intersection of Global tech, India Tech and AI.

Delivered 8 AM. Daily.
nextbigwhat We would like to show you notifications for the latest news and updates.
Allow Notifications